According to the details, two antiviral drugs of Quid-19 manufactured by a Chinese pharmaceutical company have started medical testing on humans abroad.
The Shanghai Institute of Materia Medica, which operates under the Chinese Academy of Sciences (CAS), cited its VV116 code-named anti-covid-19 oral nucleoside drug administered to animals. The results of the experimental experiments are encouraging.
The drug is effective in preventing the spread of the virus-like virus and its delta-like strains.
Shen Jingshan, a researcher at the institute, said that the first VV116 clinical trials had been approved in Uzbekistan, adding that the drug was also being tested on humans in China.
Another drug called FB 2001 is a new compound designed and formulated based on the central protease of the coronavirus, a critical enzyme that plays a vital role in the spread of the virus.